Floatz logo

Ckd-581

Myeloma, Multiple

Chong Kun Dang PharmaceuticalPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myeloma, Multiple cohort.

Asset / SponsorPhaseRating
Avelumab
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Ckd-581 is also rated in:

LeucogenDormant
CCC
Indicative ·
53 / 100
View asset →
RibociclibDormant
CCC
Indicative ·
53 / 100
View asset →
Breast CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →